Diagnosing and monitoring infectious diseases
Given the destructive capabilities of infectious diseases and their ability to spread, early and accurate diagnosis is crucial, while monitoring blood levels of infectious agents like bloodbourne viruses is crucial to assess effectiveness of antiviral treatment.
As the world leader in in-vitro diagnostics, Roche offers the widest range of tests based on real-time polymerase chain reaction (RT-PCR) technology for detecting and monitoring infectious diseases. These are based on our deep insights into the mechanisms of infectious diseases and our expertise in molecular diagnostics.
For both hepatitis B and C, the concentration of hepatitis B virus (HBV) and hepatitis C virus (HCV), respectively, is an indication how a patient responds to antiviral treatment.
Another test in the same product range enables the rapid, reliable and routine detection and monitoring of HIV-1.
Immunocompromised individuals, like transplant and AIDS patients, are at high risk for developing severe CMV infections that can lead to a higher rate of morbidity and mortality.
Roche is proud to provide products that safeguard blood and blood products, helping prevent infectious diseases from being transmitted through blood transfusions.
In the intensive care field, our aim is to provide rapid and reliable detection and identification of 25 different pathogens which are responsible for 90% of all nosocomial systemic infections. The test is the first of its kind to use PCR technology and can detect and identify both bacterial and fungal sepsis pathogens in less than six hours.